Clinical importance of genetic polymorphism of drug oxidation

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 291-300

  Edeki, Timi ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORPROPAMIDE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; NORCLOMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE;

DRUG METABOLISM; DRUG OXIDATION; GENETIC POLYMORPHISM; HUMAN; REVIEW;

BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; ETHNIC GROUPS; HUMANS; MENTAL DISORDERS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS;

EID: 0029834060     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Chapman CJ. Drugs and genes. Therapeutic implications. Drugs 1977; 14:120-127.
2. Johansson I, Ludqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
3. Edeki T, Brase D. Phenytoin disposition and toxicity. Role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995; 27:449-469.
4. Shahidi NT. Acetophenetidin-induced methemoglobinemia. Ann NY Acad Sci 1968; 151:822-832.
5. Mahgoub A, Idle JR, Dring LG, Lancaster R. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
6. Eichelbaum M, Spannbrucker N, Steinecker B, Dengler HJ. Defective N-oxidation of sparteine in man. A new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-187.
7. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992; 0:1471-1478.
8. Smith RL. Discovery of the genetic polymorphism of drug oxidation. Xenobiotica 1986; 16:361-365.
9. Eichelbaum M, Spannbrucker N, Dengler HJ. Lack of N-oxidation of sparteine in certain healthy subjects. Sixth International Congress of Pharmacology; 1975 July 20-25; Helsinki. 1975: 1071.
10. Eichelbaum M. Polymorphism of drug oxidation in man: novel findings. Trends Pharmacol Sci 1981.
11. Al-Sereiti MD, Edeki T, Liedo P, Turner P. The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers. Int J Clin Pharmacol Res 1990; 6:339-345.
12. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive B-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. J Am Med Assoc 1995; 274:1611-1613.
13. He N, Edeki T. Polymorphism of dextromethorphan oxidation in African Americans [Abstract]. J Invest Med 1995; 43:256A.
14. Woosely RL, Roden DM, Duff HJ, et al. Coinheritance of deficient oxidative metabolism of encainide and debrisoquine. Clin Res 1981; 29:501A.
15. Penno MB, Dvochik BH, Vesell ES. Genetic variation in rates of antipyrine metabolism formation. A study in uninduced twins. Proc Natl Acad Sci USA 1981; 78: 5193-5196.
16. Evans DAP, Harmer D, Downham DY, et al. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analyzing bimodal distributions. J Med Genet 1983; 20:321-329.
17. Oates NS, Shah RR, Idle JR, Smith RI. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol 1982; 32:81-89.
18. Distlerath LM, Reilly PEB, Martin AV, et al. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin o-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260:9057-9067.
19. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1992; 53:401-409.
20. Otton V, Schadel M, Cheung S, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54:463-472.
21. Steen VM, Andreassen OA, Daly AK, et al. Detection of the metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5:215-223.
22. Gonzalez FJ, Skoda CR, Kimura SM, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-446.
23. Skoda CK, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450 dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drug. Proc Natl Acad Sci USA 1988; 85:5240-5243.
24. Broly F, Gaedigk A, Heim M, et al. Debrisoquine sparteine hydroxylation genotype and phenotype. Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-558.
25. Inaba T, Otton SV, Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther 1980; 27:547-549.
26. Inaba T, Vinks A, Otton SV, Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 1983; 33:394-399.
27. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31:184-186.
28. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism. Cosegregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
29. Jacqz E, Hall SD, Branch RA. Genetically determined polymorphisms in drug oxidation. Hepatology 1986; 6:1020-1032.
30. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism. Clin Asp Pharmacol Ther 1990; 46:377-394.
31. Evans DAP, Maghoub A, Sloan TP, et al. A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105.
32. Idle J, Smith RL. The debrisoquine hydroxylation gene. A gene of multiple consequence. Am Soc Pharmacol Exp Ther 1984; 80:48-164.
33. Brosen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985; 57:357-360.
34. Eichelbaum M, Reetz K-P, Schmidt EK, Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica 1986; 16:405-481.
35. Eichelbaum M, Baur MP, Dengler HJ, et al. Chromosome assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23:455-458.
36. Karlaganis G, Kupfer A, Preisig R. Urinary bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation. Br J Clin Pharmacol 1984; 17:470-473.
37. Harmer D, Pevans DA, Ezc LC, et al. The relationship between the acetylator and the sparteine hydroxylation polymorphisms. J Med Genet 1986; 23:155-156.
38. Park BK, Eichelbaum M, Ohnhaus EE. 6-beta hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine [Letter]. Br J Clin Pharmacol 1982; 13:737-740.
39. Ayesh R, Scandding G, Brostoff J, et al. Stability of the debrisoquine metabolic ratio to immunoperturbation by influenza and pneumococcus vaccines [Abstract]. Br J Clin Pharmacol 1988; 25:141P.
40. Bechtel YC, Joanne C, Grandmottet M, Bechtel PR. The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of debrisoquine. Clin Pharmacol Ther 1988; 44:408-417.
41. Sloan TP, Lancaster R, Shann RR, et al. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 1983; 5:443-450.
42. Eichelbaum M, Mineshita S, Ohnshaus EE, Zekorn C. The influence of enzyme induction Hon polymorphism sparteine oxidation. Br J Clin Pharmacol 1986; 22:49-53.
43. Meese CO, Bertilsson L, Fisher C, et al. Stereoselectivity of 4-hydroxydebrisoquine enantiomer formation in relation to debrisoquine phenotype. Presented at Third World Conference on Clinical Pharmacology and Therapeutics; July to August 1986.
44. Eichelbaum M. Defective oxidation of drugs. Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1982; 7:1-22.
45. von Moltke L, Greenblatt D, Court M, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamme. Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-131.
46. Pierce DM, Smith SE, Franklin RA. The pharmacokinetics of Indoramin and 6-hydroxyindoramin on poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 1987; 33:59-65.
47. Baumann P, Jonzier-Percy M, Koeb L, et al. Amitriptyline pharmacokinetics and clinical response: 11. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1:102-112.
48. Silas JH, Lennard MS, Tucker GT, et al. Why hypertensive patients vary their response to oral debrisoquine. Br Med J 1977; 1:422-425.
49. Shah RR, Oates NS, Idle JR, et al. Prediction of subclinical prehexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. Am Heart J 1988; 105:159-161.
50. Oates NS, Shah RR, Idle JR, Smith RI. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol 1982; 32:81-89.
51. Shah RR, Oates NS, Idle JR, Smith RL. Genetic impairment of phenformin metabolism. Lancet 1980; 1:1147.
52. Wiholm B, Alvan G, Bertilsson L, et al. Hydroxylation of debrisoquine in patients with lactic acidosis after phenformin. Lancet 1981; 1:1098-1099.
53. Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype: A major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307:1558-1560.
54. Lennard MS, Jackson PR, Freestone S, et al. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1982; 17:679-685.
55. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol, and atenolol. Xenobiotica 1986; 16:435-447.
56. Lennard MS, Iyun AO, Jackson PR, et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
57. Dayer P, Kubli A, Kupfer A, et al. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 1982; 13:750-751.
58. Dayer P, Balant L, Kupfer A, et al. Contribution of the genetic status of oxidation metabolism to variability in the plasma concentrations of β-adrenoceptor blocking agents. Eur J Clin Pharmacol 1983; 24:797-799.
59. Raghuram TC, Koshakji RP Wilkinson GR, Wood AJJ. Polymorphic ability to metabolize propranolol alters 4 hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 1984; 36:51-56.
60. McGourty JC, Silas JH. Metoprolol metabolism and debrisoquine oxidation polymorphism: Population and family studies. Br J Clin Pharmacol 1985; 20:555-566.
61. McGourty JC, Silas JH, Fleming JJ, et al. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolisers of debrisoquin. Clin Pharmacol Ther 1985; 38:409-413.
62. Mikus G, Ha HR, Vozen S, et al. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol 1986; 31: 69-72.
63. Steiner E, Bertilsson L, Sawe J, et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 431-435.
64. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239-248.
65. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90-98.
66. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: 1. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10:48-50.
67. Gram LF, Overo KE. Drug interaction. Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972; 1:463-465.
68. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation text predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15:388-390.
69. Spina E, Birgersson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984; 36:677-682.
70. Spina E, Steiner E, Ericsson O, Sjoqvist F, Hydroxylation of desmethylimipramine. Dependence on debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1987; 41:314-319.
71. Derenne F, Joanne C, Vandel S, et al. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 1989; 36:53-58.
72. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992; 14:1-8.
73. Llerena A, Herraiz AG, Cobaleda J, et al. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol 1993; 54: 606-611.
74. Ritchie JC, Sloan TP, Idle JP, Smith RL. Toxicological implications of polymorphic drug metabolism. Ciba Found Symp 1980; 76:219-244.
75. Woosely RL, Roden DM, Duff HJ, et al. Coinheritance of deficient oxidative metabolism of encainide and debrisoquine. Clin Res 1981; 29:501A.
76. McAllister CB, Wolfenden HT, Aslanian WS, et al. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica 1986; 16:483-490.
77. Yue QY, Svensson JO, Alm C, et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br Clin Pharmacol 1989; 28:639-645.
78. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990; 48:686-693.
79. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine. A case report with implication for treatment with nortriptyline and other tricyclic antidepressants Ther Drug Monit 1985; 7:478-480.
80. Johansson I, Ludqvist E, Bertilsson L, et al. Inherited application of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
81. Agundez J, Ledesma MC, Ladero JM Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57:265-269.
82. Woolhouse NM, Eichelbaum M, Oates NS, et al. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.
83. Agundez J, Martinez C, Ledesma MC, et al. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994; 55:412-417.
84. Dayer P, Kubli A, Kupfer A, et al. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 1982; 13:750-751.
85. Evans WE, Relling MV, Rahman A, et al. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative metabolism phenotypes in Black Americans. J Clin Invest 1993; 91:2150-2154.
86. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50:308-313.
87. Eichelbaum M, Baur MP, Dengler HJ, et al. Chromosome assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23:455-458.
88. Woolhouse NM, Andoh B, Mahgoub A, et al. Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 1979; 26:584-591.
89. Mbanefo C, Bababunmi EA, Mahgoub A, et al. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10:811-818.
90. Sommers DK, Monerieff J, Avenant J. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of Southern Africa. Hum Toxicol 1988; 7:273-276.
91. Simooya O, Njunju E, Hodjegan AR, et al. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3:205-208.
92. Arias TD, Inaba T, Cooke RG, Jorge LF. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians. A case of genetic divergence with tentative phylogenetic time from for the pathway. Clin Pharmacol Ther 1988; 44: 343-352.
93. Jorge LF, Arias TD, Inaba T, Jackson PR. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama. Br J Clin Pharmacol 1990; 30:281-285.
94. Horai Y, Nakano M, Ishizaki T, et al. Meloprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects. Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
95. Bertilsson L, Lou YQ, Yun-Long D, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
96. Evans DA, Krahn P, Narayanan N. The mephenytion (cytochrome P-450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995; 5:64-71.
97. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 10: 402-408.
98. Ishizaki T, Eichelbaum M, Horai Y, et al. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987; 23:482-485.
99. Wanwimolruk S, Pratt EL, Denton JR, et al. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacokinetics 1995; 5:193-198.
100. Weerasuriya K, Jayakody RL, Smith AD, et al. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994; 38:466-470.
101. Wanwimolruk S, Patamasucon P, Lee EFD. Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 1990; 29:244-247.
102. Guttendorf RJ, Britto M, Blouin RA, et al. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 1990; 29: 373-380.
103. Peart GF, Boutagy J, Shenfield GM. Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 1986; 21:465-471.
104. Leclercq V, Desager JP, Nieuwenhuyze YV, Harvengt C. Prevalence of drug hydroxylator phenotypes in Belgium. Eur J Clin Pharmacol 1987; 33:439-440.
105. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982; 31:23-29.
106. Kuvet RA, Svenson JO, Bertilsson L, Sjoqvist. Polymorphism of debrisoquine and mephenytion hydroxylation among Estonians. Pharmacol Toxicol 1993; 72:113-115.
107. Arvela P, Kirjarinta M, Karki N, Pelkonen O. Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol 1988; 26:601-603.
108. Viry MV, Fournier B, Siest G, Galteau MM. Dextromethorphan O-demethylation in a large number of French Caucasian families. Pharmacogenetics 1992; 2:135-138.
109. Larrey D, Amouyal G, Tinel M, et al. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 1987; 24:676-679.
110. Jacqz E, Dulae H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988; 35:167-171.
111. Freche JP, Dragacci SM, Petit AM, et al. Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a french population Eur J Clin Pharmacol 1990; 39:481-485.
112. Hildebrand M, Seifert W, Reichenberger. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36: 315-318.
113. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4:209-218.
114. Brosen K. Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol 1986; 22:415-419.
115. Clasen K, Madsen L, Brosen K, et al. Sparteine and mephenytoin oxidation. Genetic polymorphisms in East and West Greenland. Clin Pharmacol Ther 1991; 49: 624-631.
116. Spina E, Campo GM, Avenoso A, et al. CYP2D6 related oxidation polymorphism in Italy. Pharmacol Res 1994; 29:281-289.
117. Benitez J, Llerena A, Cobaleda J. Debrisoquin oxidation polymorphism is a Spanish population. Clin Pharmacol Ther 1988; 44:74-77.
118. Henthorn TK, Benitez J, Avram MJ, et al. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 1989; 45:328-333.
119. Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45:495-498.
120. Al-Hadidi HF, Irshaid YM, Rawashdeh NM. Metoprolol α-hydroxylation is a poor probe for debrisoquin oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 1994; 47:311-314.
121. Irshaid YM, Al-Hadidi HF, Rawashdeh NM. Dextromethorphan O-demethylation polymorphism in Jordanians. Eur J Clin Pharmacol 1993; 45:271-273.
122. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi-Arab population. Xenobiotica 1980; 10:819-825.
123. Bozkurt A, Basci N, Isimer A, et al. Polymorphic debrisoquin metabolism in a Turkish population. Clin Pharmacol Ther 1994; 55:399-401.
124. Gorgia AE, Baint LP, Genet C, et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986; 31:449-455.
125. Nielson K, Brosen K, Hansen M, Gram L. Single-dose kinetics of clomipramine. Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55:518-527.
126. von Molte L, Greenblatt D, Coteau-Bibbo M, et al. Inhibition of desipramine hydroxylation in vitro by serotonin reuptake inhibitor antidepressants, and quinidine and ketoconazole. A model system to predict drug interacts in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
127. Brosen K, Gram L. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1987; 37:155-160.
128. Brosen K, Zeugin T, Meyer U. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49:609-617.
129. Huang ML, Peer AV, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-268
130. Llerena A, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14:261-264.
131. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15:11-17.
132. Kallio J, Huupponeen R, Pyykko K. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide. Eur J Clin Pharmacol 1990; 39:93-95.
133. Woodhouse N, Yamoah K, Mellstrom B, et al. Nortriptyline and debrisoquine hydroxylations in Ghanian and Swedish subjects. Clin Pharmacol Ther 1984; 36: 374-378.
134. Drohse A, Bathum L, Brogen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989; 27:620-625.